Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells
Cellular Physiology and Biochemistry2018Vol. 45(4), pp. 1515–1528
Citations Over TimeTop 10% of 2018 papers
Pranav Gupta, Yunkai Zhang, Xiaoyu Zhang, Yi‐Jun Wang, Kimberly Lu, Timothy L. Hall, Richard Peng, Dong‐Hua Yang, Ni Xie, Zhe‐Sheng Chen
Abstract
Voruciclib is currently a phase I clinical trial drug. Our findings strongly support its potential use in combination with conventional anti-cancer drugs for cancer chemotherapy.
Related Papers
- → The controversial role of ABC transporters in clinical oncology(2011)230 cited
- → Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2)(2006)84 cited
- → 9-Deazapurines as Broad-Spectrum Inhibitors of the ABC Transport Proteins P-Glycoprotein, Multidrug Resistance-Associated Protein 1, and Breast Cancer Resistance Protein(2017)64 cited
- → Induction of the ABC-Transporters Mdr1/P-gp (Abcb1), Mrp1 (Abcc1), and Bcrp (Abcg2) during Establishment of Multidrug Resistance Following Exposure to Mitoxantrone(2005)51 cited
- → Drug Resistance Transporters in AML(2007)1 cited